Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that its next-generation PSMA-PET imaging 1 agent for prostate cancer, Gozellix® (kit for the preparation ...

The Food and Drug Administration (FDA) has approved Xifyrm ™ (meloxicam injection) for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID ...

Combination vaccines are recommended by health authorities worldwide to reduce the number of jabs given to children while ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Treatment with retifanlimab plus carboplatin-paclitaxel statistically significantly reduced the risk of progression or death by 37% compared with placebo plus carboplatin-paclitaxel.

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

School of Science, College of Science, Engineering and Health, RMIT University, Melbourne, VIC 3000, Australia Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC ...

Nevertheless, concerns about the safety of DES still exist. Objective: To investigate the vascular pathology and transcriptional responses to sirolimus and paclitaxel in a murine model for restenosis ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

Absolute Risk Reduction (ARR): the absolute difference in the percentage of patients who did not develop grade 4 neutropenia in the test group versus the control group.